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The COVID-19 pandemic triggered an unparalleled pursuit of vaccines to induce specific adaptive immu-
nity, based on virus-neutralizing antibodies and T cell responses. Although several vaccines have been
developed just a year after SARS-CoV-2 emerged in late 2019, global deployment will take months or even
years. Meanwhile, the virus continues to take a severe toll on human life and exact substantial economic
costs. Innate immunity is fundamental to mammalian host defense capacity to combat infections. Innate
immune responses, triggered by a family of pattern recognition receptors, induce interferons and other
cytokines and activate both myeloid and lymphoid immune cells to provide protection against a wide
range of pathogens. Epidemiological and biological evidence suggests that the live-attenuated vaccines
(LAV) targeting tuberculosis, measles, and polio induce protective innate immunity by a newly described
form of immunological memory termed “trained immunity.” An LAV designed to induce adaptive immunity
targeting a particular pathogen may also induce innate immunity that mitigates other infectious diseases,
including COVID-19, as well as future pandemic threats. Deployment of existing LAVs early in pandemics
could complement the development of specific vaccines, bridging the protection gap until specific vac-
cines arrive. The broad protection induced by LAVs would not be compromised by potential antigenic drift
(immune escape) that can render viruses resistant to specific vaccines. LAVs might offer an essential tool to
“bend the pandemic curve,” averting the exhaustion of public health resources and preventing needless
deaths and may also have therapeutic benefits if used for postexposure prophylaxis of disease.
trained immunity | nonspecific effects of live vaccines | interferon | SARS-CoV-2
Like all living organisms, human beings are exposed
to a variety of pathogens. How do we almost always
stop the infections by different microbes, even those
that we have never encountered before? When we are
infected, why do the vast majority of pathogens disap-
pear after only a few days or a week, causing very mild
or no disease? Obviously, this cannot be due to the
virus simply running out of cells to infect. It also cannot
be a result of a very specific adaptive immune response
consisting of B lymphocytes and the antibodies they
produce, and of T lymphocyte-mediated cellular immu-
nity. Antibodies develop through a complex multistep
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process and reach their needed levels of activity only after many days
or weeks (1). Both specific antibodies and T cells are crucial for the
host defense against prolonged infections, but they need time to be
activated, and they are far less, if at all, involved during the first hours
and days of an infection.
Our innate immune response represents the first line of defense
against invading pathogens. Clinically, the fever that is often the first
symptom of a viral infection is also the first manifestation of our
antiviral defense system in action. Moreover, for 95% of all
species—including plants and all invertebrate animals—innate
immune responses are the only protection available (2, 3). Only
vertebrates developed lymphocytes to mediate adaptive immune
responses. These cells form the backbone of our highly pathogen-
specific adaptive immunity that protects us when our first line of
defense fails to keep the invaders at the gate. Unlike the days and
weeks needed to activate adaptive immunity, its innate counterpart
engages within minutes and hours to protect our bodies from a wide
spectrum of pathogens (4). It is clear that innate immunity in the
absence of antibodies and T cellular immune response is sufficient
to prevent illnesses caused by many systemic pathogens from ad-
vancing, while the adaptive immune responses are crucial when the
first line of defense is overcome (Fig. 1). The outcome of any infec-
tion depends on the race between the pathogen and the host de-
fense systems. It stands to reason that increasing the efficacy of
innate immunity and enhancing defense pathways abrogated by
SARS-CoV-2 could substantially mitigate infection from the start or
potentially even prevent them.
Table 1 presents a comparison of innate and adaptive immune
systems. The power of innate immunity lies in its broad, nonspe-
cific activation, and the ability to inhibit multiple pathogens. It is
based on sensors called pattern-recognition receptors (PRRs) that
recognize pathogen-associated molecular patterns (PAMPs) and
activate multiple pathways that render a host resistant to infection
(5). In the case of RNA viruses like SARS-CoV-2, the recognition
trigger lies within the nucleotide sequence of the RNA of the virus.
The response is immediate and begins with stimulating key host
cellular receptors, such as Toll-like receptor (TLR)3 and TLR7, lead-
ing to activation of natural killer (NK) cells, monocytes, and
expression of interferon (IFN) genes. In turn, IFN serves as a me-
diator by binding IFN receptors on the host cell surface and
launching expression of IFN-stimulated genes (ISG) (6). Proteins
coded by these genes induce the so-called antiviral state by mak-
ing cells unable to support virus replication.
Stimulation of PRRs by PAMPs leads to the induction of a family
of cytokines called IFNs. There are three classes of IFN molecules,
including type 1 (α, β, e, κ, ω), type 2 (γ), and type 3 (λ). In most
cases, stimulation of PRRs by PAMPs initially leads to the induction
of type 1 IFN, which in turn leads to the production of several
ISGs. ISGs have pleiotropic effects and can lead to induction of
the cellular direct antiviral state, macrophage activation, stimula-
tion of NK cells and cytotoxic T lymphocytes, and the proliferation
of T-helper cells (7). Type 1 IFNs also have antiinflammatory ef-
fects due to down-regulation of several proinflammatory cyto-
kines, including of tumor necrosis factor-α and interleukins 1
and 8. Exogenous recombinant IFNs have been approved to treat
several viruses, including human papilloma virus, hepatitis C virus,
and hepatitis B virus.
In contrast, the defining characteristic of the adaptive immune
response is its singular pathogen-specificity and immunologic
memory that allows the body to produce antibodies and activate
T cells faster if reinfected by that particular pathogen. The induc-
tion of adaptive immunity that may last a lifetime (e.g., measles,
polio) is the underlying principle behind prophylactic vaccines.
However, the very high specificity of adaptive immunity is the
“Achilles heel” of vaccines, because though some degree of
cross-reactivity may exist (8), they protect predominantly against
one pathogen, and often against only one specific strain. For this
reason, vaccines relying on protective antibodies and T cells may
lose effectiveness if mutations emerge in viral protective epitopes.
If this happens, new pathogen-specific vaccines will have to be
developed from scratch (as is the case with influenza vaccines). In
contrast, viruses cannot easily develop resistance to innate immu-
nity that will continue ensuring broad protection against patho-
gens, even if they undergo antigenic drift.
The durability and memory of the adaptive immunity system
are often cited as its superiority over innate immune responses.
Fig. 1. This figure illustrates how a healthy innate immune system protects most people within the population against infections.With an already robust
or trained innate immune system, the overwhelming majority of people infected with a new pathogen, such as SARS-CoV-2, are able to eradicate the
infection early during the asymptomatic or mildly symptomatic phase of infection. Without prior exposure or vaccination (e.g., with a messenger RNA
vaccine), adaptive immunity takes days to weeks to kick in and is often suppressed in severe cases, contributing to a self-perpetuating and injurious
hyperinflammatory response. The innate immune system often loses potency with age, certain comorbidities, immunosuppression, and with genetic
susceptibility.
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However, recent results summarized in this report will show that
these distinguishing characteristics between adaptive and innate
stimuli may not be as widely apart as first thought. Indeed, some
vaccines (e.g., influenza and HIV) induce adaptive immune re-
sponse that lasts only months (9, 10), and long-term innate immu-
nity activation may also last that long. Innate immunity is also now
known to adapt to previous insults, indeed to develop a de facto
innate immune memory, that facilitates stronger responses to sub-
sequent pathogen attacks of heterogeneous nature (11). This innate
immune memory, also called “trained innate immunity,” is medi-
ated by epigenetic, transcriptional, and functional reprogramming
of innate immune cells and their bone marrow progenitors.
Trained innate immunity will be described below in more detail.
In this article, we propose that during a pandemic (or epidemic),
medical science could rapidly harness the power of innate immu-
nity to induce partial protection against new (such as SARS-CoV-2)
or reemerging pathogen threats and suggest that this might be
achieved through the repurposing of some established live-
attenuated vaccines (LAVs), which are powerful inducers of
innate immunity.
Innate Immunity Is Key in Controlling the SARS-CoV-2
Pandemic
Several observations make clear the central importance of innate
immunity in controlling SARS-CoV-2. First, human coronaviruses,
including SARS, Middle Eastern respiratory syndrome (MERS), and
SARS-CoV-2 have evolved special mechanisms to suppress immune
responses. The viruses devote part of their genetic information to
code for proteins that specifically target our innate immune mech-
anisms, namely the IFN response pathways, by inhibiting TLR3/7
signaling (12–15). Second, the expression of human genes favoring
innate immune responses correlates with better clinical response.
Indeed, in one study these were the only immune response genes
correlated with a favorable prognosis (16). Third, specific mutations
that reduce IFN production or function correlate with severe mor-
bidity and mortality (17). In line with other studies that show a cor-
relation between innate immune expression and better prognosis
are the findings that correlate severe morbidity and mortality with
mutations that lead to faulty type I IFN production or production of
neutralizing autoantibodies targeting type I IFNs (18, 19). Consistent
with this, therapeutic use of type I IFN (IFN-x2b) in the viral phase of
COVID-19 reduced the duration of detectable virus in the respira-
tory tract and improved the prognosis (20, 21).
Finally, control of coronaviruses by bats is almost exclusively
associated with an appropriate balancing of innate immune re-
sponses between resistance and tolerance. Many bat species can
safely harbor coronaviruses that cause diseases in other mammals,
including humans (22). Bats show an unusually high number of ac-
tivated NK cells, as well as a constitutive expression of IFN. These
studies also show a lesser inflammatory response to these viruses
(23). Collectively, these findings present very strong arguments that
innate immunity is critical to the control of coronavirus diseases. At
the onset of the pandemic, this provoked some of us to consider
strategies based on stimulation of innate immunity as a comple-
ment to disease-specific vaccines by bridging the period until their
development and to overcome some of their limitations (11, 24, 25).
Specific Vaccines: A Crucial Tool Against COVID-19, yet
More Help Is Needed
Vaccines are among our most successful public health interven-
tions (26), allowing us to overcome many deadly contagions, and
avoid “plague”measures of shutdowns and social distancing. We
are laser-focused on the pursuit of a vaccine as the antidote to the
clinical carnage, social devastation, and economic crisis caused by
SARS-CoV-2. The rapid development of several highly effective
vaccines using advanced new mRNA technology is an extraordi-
nary achievement in the battle against COVID-19. It is hoped that
widespread vaccination will significantly decrease the spread of
SARS-CoV-2. However, mass deployment cannot happen in time
to save tens of thousands human lives, tens of millions more jobs,
and avert the severe hunger facing several million children. Many
hurdles remain.
First, specific COVID-19 vaccines appear to be highly protec-
tive, in some cases reaching 95% clinical efficacy. However, efficacy
refers only to prevention of illness, not to prevention of infection or
onward spread, the real key to reaching herd immunity. It will take
several months to undertake postmarketing evaluation to ascertain
whether vaccines stop virus transmission in younger adults, the age
group responsible for most spread. As preventing infection requires
a higher level of antibodies than preventing serious disease,
the effectiveness for preventing infection is likely to be lower
than clinical efficacy. The safety of specific vaccines in pregnant
women—a high-risk group representing a significant proportion of
healthcare and aged care workforce—has not yet been established.
If vaccines are effective in preventing transmission, achieving
herd immunity will require 60 to 70% of the population to be
vaccinated (an estimate that is being revised upwards) (27).
Second, while the storage requirement at very cold temperatures
and need for an ultracold chain for mRNA vaccine present difficulties
(28), a bigger challenge is vaccine nationalism: the hoarding of
vaccines by rich countries while the spread continues in poorer
countries, just a plane ride away. An even bigger challenge is pro-
ducing enough vaccines for the world’s population, hindered by
intellectual property protections that are impeding the scale-up of
the first successful vaccines and limiting access to billions of people.
Third, even once these obstacles are overcome, turning vaccines
into vaccinations is contingent upon trust. Even the best biomedical
solutions require social traction for uptake. The politicization of the
pandemic, erosion of trust in authorities and vaccines, together with
concerns about the safety of newly developed vaccines are likely to
limit uptake and prevent creation of population immunity (29). The
use of time-tested LAVs could help to overcome this problem.
Table 1. Comparing the characteristics of the two forms of immune response
Innate Adaptive
Mediated by both myeloid and lymphoid (NK, T) cells Involves lymphoid cells (B and T lymphocytes)
Based on direct phagocytosis and killing of microbes, release of cytokines
and chemokines, NK-mediated killing of virus-infected cells
Mechanistically involve antibodies and specific T cells
Works almost immediately Takes 1 to 2 wk to develop following exposure to a pathogen or vaccine
Present in all multicellular organisms System is present in vertebrates but not in invertebrates or plants
Broadly specific, can be effective against groups of microorganisms Specific to one microorganism or even strain
Chumakov et al. PNAS | 3 of 10
































Unlike lifelong immunity to polio, measles, and smallpox, im-
munity to coronaviruses appears to be evanescent, lasting only
months to years (30–32). Reinfection cases underscoring limited
natural immunity are increasingly reported. Furthermore, the ex-
tent to which the virus can mutate has not been clearly elucidated.
Mutations in new variant strains, such as 501.V2, may affect vac-
cine efficacy, which combined with increased contagiousness
would raise herd immunity thresholds, making it more difficult to
reach. Other mutations may have the potential to stymie durable
antibody-dependent immunity (33).
Another major obstacle to eliminating an infectious disease
presents when the pathogen has substantial nonhuman reservoirs.
Some other major infectious pathogens, like polio and measles,
do not have notable animal reservoirs, and despite very effective
vaccines we have not been able to eradicate them. In contrast,
SARS-CoV-2 is able to cross between humans and multiple animal
species, including pangolins, bats, turtles, snakes, mink, cats, and
gorillas (34).
Vaccines based on induction of adaptive immunity response
are very important. In the absence of effective treatment or reli-
able cure, the capacity of vaccines to prevent serious disease and
death is especially vital for vulnerable groups, such as the elderly.
However, such new vaccines generating specific antibodies and
T cells cannot be immediately available during this or any future
pandemic. These caveats to a future dependent solely on vac-
cines based on adaptive immunity demand an expansion of our
current protective armament.
LAVs as Potent Inducers of Innate Immunity:
Epidemiological Evidence for Beneficial Nonspecific
Effects of Vaccines
The prevailing paradigm in vaccinology focuses almost exclu-
sively on adaptive immunity based on pathogen-specific anti-
bodies and T cells. However, vaccine impact is also achieved
through a series of beneficial nonspecific effects (NSE). Accumu-
lating evidence suggests that LAVs provide protection not only
against the target infectious agent, but also against a broad range
of other pathogens (35).
The first indication came from observations made almost 100 y
ago in Paris with Bacillus Calmette–Guérin (bacillus Calmette–
Guérin) vaccine against tuberculosis (36). Calmette, one of the inven-
tors of bacillus Calmette–Guérin, noted a fourfold greater decline in
child mortality not caused by tuberculosis in bacillus Calmette–Guérin-
vaccinated children compared with unvaccinated peers.
In the 1950s to 1960s, early clinical trials of oral polio vaccine
(OPV) revealed nonspecific protective effects of immunization.
Multicenter prospective clinical trials of OPV during seasonal
outbreak of influenza showed that vaccination with OPV reduced
the incidence of influenza two- to fourfold (33, 34).
A systematic examination of the beneficial NSEs of LAVs
started with the discovery that a measles vaccination campaign in
1979 in Guinea-Bissau, West Africa, reduced all-cause mortality by
almost 70%, much more than could be explained by the pre-
vention of measles infection (37). The finding, when confirmed in
other low-income settings, led to the formulation of the hypoth-
esis that measles vaccine has NSE, strengthening the immune
system and providing increased protection against a broad range
of infections (38). Since then, decades of clinical-epidemiological
observations support the beneficial protective effect of LAVs and
in particular bacillus Calmette–Guérin, OPV, smallpox vaccine,
and measles vaccines (35, 39). For example, randomized trials
showed that bacillus Calmette–Guérin (40), live measles vaccine
(41), and OPV (42) reduce all-cause mortality much more than
anticipated from their effects on the target disease alone. His-
torical cohort studies found the same beneficial NSE of smallpox
vaccine (38). The reduced mortality is mainly due to a reduction in
mortality due to respiratory infections (35). Vaccinations against
tuberculosis and smallpox have been associated with better long-
term survival (38). Intriguingly, the beneficial NSE of LAV may
become more pronounced with subsequent doses (43). For ex-
ample, OPV campaigns in West Africa have been associated with
a 25% reduction in all-cause mortality, with each additional dose
reducing mortality by a further 14% (44).
Table 2 compares characteristics of protective effects of LAVs
based on stimulating innate immunity and pathogen-specific
vaccines inducing adaptive immune responses. Difficulty in char-
acterizing off-target effects of LAVs, controversy over needing to
change immunization schedules, concern over limited manufac-
ture of nonprofitable vaccines, as well as potential contribution to
vaccine hesitancy have delayed much needed large-scale ran-
domized controlled trials and research into NSE of vaccines.
Emerging evidence and recent publications of robust data sup-
port the association between bacillus Calmette–Guérin, neonatal
mortality, and malaria risk (45–47), and underscore the imperative
for research to examine and exploit this effect.
In 2014, a World Health Organization-commissioned review at
the recommendation of the Strategic Advisory Group of Experts
on vaccines concluded that LAVs reduced child mortality by more
than expected by specific prevention of the target diseases (37).
The same patterns were observed in high-income settings: For
example, in the United States, having a live vaccine as the most
recent vaccine was associated with a halving of the risk of hospi-
talization for nontargeted infections (48). The review advised more
research regarding the beneficial heterologous effects of LAVs, and
in particular if a different sequence of immunizations could exploit
beneficial effects (48). These studies have yet to be conducted.
Animal studies provide additional evidence of the off-target
protective effects of LAVs. For example, immunization of mice
with cold-adapted live-attenuated influenza H3N2 vaccine pro-
tected them from disease upon challenge with respiratory syn-
cytial virus (RSV), accompanied by induction of cytokines and
infiltration of respiratory tract with leukocytes (49). Immunization
with inactivated influenza vaccine as a control did not induce a
protective effect against RSV. The effect of attenuated influenza
vaccine was reduced in TLR3/TLR7− mice, supporting other evi-
dence that these pathways are involved in the activation of innate
immunity. An experimental vaccine against whooping cough
made from live-attenuated Bordetella pertussis also prevented
inflammation caused by unrelated respiratory infections, such as
influenza and RSV in mice (50), and reduced noninfectious in-
flammation, including contact dermatitis (51).
Trained Innate Immunity: Immunological Mechanisms
Two important immunological mechanisms are believed to con-
tribute to the beneficial NSE of live vaccines: heterologous cellular
immunity and trained innate immunity. In the 1960s and 1970s,
the seminal studies of Mackaness et al. (52, 53) demonstrated
protection induced by bacillus Calmette–Guérin vaccination
against infections with Listeria monocytogenes or Salmonella
typhimurium. Similar heterologous protection against infections
dependent on T cell activation has been later reported in addi-
tional studies (for review, see refs. 54, 55). Interestingly, some of
these studies have shown that interaction of T cells with macro-
phages is crucial for this protection to be effective, raising the
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possibility of long-term adaptation and increased antimicrobial
activity in innate immune cells (56).
Accumulating recent evidence suggests that some types of
vaccines, especially LAVs that closely mimic natural infection, in-
duce long-term enhancement of antimicrobial function of innate
immune cells that contributes to protection from subsequent reinfec-
tion. The term “trained immunity” refers to this functional reprog-
ramming of innate immune cells, such as myeloid and NK-cells (57).
The induction of trained immunity by LAVs is mediated by a
complex, finely tuned, interplay between immunological signals, cell
metabolism, and epigenetic reprogramming (58). Cellular metabo-
lism is rewired to increase glycolysis (59), glutaminolysis (60), and
cholesterol synthesis (61) to provide the energy and building blocks
for cells, and for modulation of epigenetic processes. At the same
time, chromatin architecture is changed at the loci encoding genes
important for host defense, with more open chromatin characterized
by the histone marks H3K4me1, H3K4me3, and H3K27Ac (62). The
methylation and acetylation of histones after vaccination with a LAV
“mark” the gene necessary for host defense: upon infection with a
pathogen, these genes will be transcribed quicker and stronger, im-
proving the immune response and the survival of the host. This pro-
cess can be compared with putting a bookmark in a book: if needed,
the book can be opened more easily at the right place (Fig. 2).
Induction of trained immunity has been reported to mediate at
least in part the nonspecific biological effects of bacillus Calmette–
Guérin vaccination through a NOD2-dependent mechanism (63).
Importantly, it has also been demonstrated that long-term func-
tional reprogramming of innate immune responses is mediated by
Table 2. Advantages and disadvantages of conventional adaptive immune response vaccines versus innate immune-stimulating
vaccines through use of “old” LAVs for the SARS-CoV-2 pandemic
Characteristic Innate broadly specific LAVs Adaptive (specific) vaccines
Economics Cheap, but likely little market value Expensive, but great market value




Safety record Known and mainly very safe Unknown for new vaccines (needs 1 to 2 y or longer)
Efficacy Clearly for their target pathogen and numerous results for broader
effects
Efficacious for SARS-CoV-2 in standard setting, still unclear in
high-risk groups and for what duration
Durability Weeks to months to years Extremely variable a few months to a lifetime
Memory Thought to be none; but recent results for bacillus Calmette–Guérin
reveal innate immune memory (trained innate immunity)
Strong for B cells (antibodies) and T cell responses
Fig. 2. The epigenetic mechanism induced by LAVs in innate immune cells and their precursors: methylation and acetylation of histones after
vaccination “mark” the gene necessary for host defense, leading to long-term changes in chromatin architecture leading to stronger expression
upon subsequent stimuli.
Chumakov et al. PNAS | 5 of 10
































transcriptional and epigenetic processes in the myeloid cell pro-
genitors in the bone marrow, explaining the long-term effect of
bacillus Calmette–Guérin on circulating myeloid cells (64, 65). The
booster effect of bacillus Calmette–Guérin on cell function extends
beyondmyeloid cells to other innate immune cell populations, such
as NK cells (66). Altogether, the accumulating evidence during the
last decade supports the concept that trained innate immunity is
responsible for a large part of the heterologous protective effects of
LAVs. Since most of this evidence has been provided by studies on
bacillus Calmette–Guérin vaccination, studies to decipher induction
of trained immunity by measles-mumps-rubella (MMR), OPV, and
other LAVs are urgently needed. In the case of MMR, it will be
important to assess the NSE of each attenuated strain separately, as
it may become important to have multiple LAVs available for serial
administration.
Of note, live-attenuated Salmonella Typhi strain Ty21a has
recently been shown to induce long-term training of innate
immunity (67).
Epidemiological Evidence for the Effects of LAVs against
COVID-19
The COVID-19 pandemic spurred research into the protective
effects of LAVs against COVID-19. A mission to China at the end
of January prompted the Director General of the World Health
Organization to consider whether bacillus Calmette–Guérin could
protect healthcare workers on the frontlines of the outbreak. In
mid-February, the world’s first conference on NSE of vaccines led
many researchers present at the conference to initiate clinical
trials of bacillus Calmette–Guérin vaccine against COVID-19 (25,
68). There are currently ∼20 bacillus Calmette–Guérin trials that
will provide estimates on the effect of bacillus Calmette–Guérin
against infections, including COVID-19, in health care workers
and elderly. Similar studies are ongoing with respect to OPV (69)
and MMR (70). Table 3 provides a listing of currently available
LAVs along with their salient characteristics.
A recent observational study of healthcare workers in Los
Angeles showed that the seroprevalence of anti–SARS-CoV-2
IgG, as well as incidence of self-reported COVID-19 symptoms,
were significantly decreased among healthcare workers with a
history of bacillus Calmette–Guérin vaccination compared with
those without bacillus Calmette–Guérin vaccination. No effect
was associated with a history of inactivated vaccines, such as
meningococcal, pneumococcal, or influenza vaccination (71).
Several observational studies have examined the association
between recent LAV vaccination and COVID-19 risk. A Dutch study
showed fewer COVID symptoms in bacillus Calmette–Guérin-
vaccinated cohorts compared with unvaccinated cohorts (72). A
study from the United Arab Emirates showed bacillus Calmette–
Guérin revaccination was associated with protection against
COVID-19 (73). A recent Mexican study found less severe illness in
individuals recently vaccinated with MMR (74).
Economic Analysis of LAVs and COVID-19
Effective response to a global pandemic is not possible without
thorough economic evaluation. Its purpose is to guide resource
allocation to where value for money is the highest, typically to
interventions that maximize outcomes per million dollars spent.
Economic evaluation of the pathogen-specific effects of vaccines
looks at costs in terms of the vaccine itself, its delivery systems
and, if the vaccine is in short supply, in terms of amount of vaccine
available.* The evaluations look at outcomes that depend on
context: cases averted, deaths averted, time off from work aver-
ted, and medical and hospitalization costs averted. Mortality re-
duction is sometimes explicitly valued in dollar terms but more
usually not (for discussion, see ref. 75). Lee et al. (76) and Li et al.
(77) provide extensive reviews of the effectiveness research un-
derpinning economic analysis of 10 important pathogen-specific
vaccines. As far as we are aware, only Byberg et al. (78) have
undertaken a cost-effectiveness analysis that explicitly incorpo-
rates vaccines’ NSE. Their analysis concluded that the NSE, in the
context of measles herd immunity, proved to be more important
in determining effectiveness and cost-effectiveness than the
intended measles-specific effect.
The economic attractiveness of LAVs to stimulate innate im-
munity and protection against COVID-19 will depend on (cur-
rently unknown) effectiveness and duration. Elaborate modeling is
sometimes utilized for economic evaluations, but the magnitude
of parameter and model uncertainty suggests that, at this point,
elaborate efforts would add little insight while adding cost in
terms of time and lack of transparency. Initial efforts should aim to
generate first order or approximate cost-effectiveness (CEA) and
benefit-cost (BCA) assessments. CEA’s typically assess cost per
death or infection averted, whereas BCAs go beyond CEA to as-
sign monetary value to reductions in morbidity and mortality.
Economic evaluations of vaccine effectiveness often center on
Table 3. Existing LAVs and their characteristics
Criteria Measles/MMR OPV Bacillus Calmette–Guérin
Route Subcutaneous Oral Intradermal
Combination
vaccines
MMR vaccine and MMR combined with
Varicella vaccine
bOPV (OPV1 and OPV3) Alone
Contraindications Immunosuppression, pregnancy, HIV with
CD4 T cell counts <15%
Immunosuppression, HIV, pregnancy Immunosuppression, active tuberculosis,
pregnancy
Adverse events Serum sickness like arthralgias. Febrile
seizures. Rare but severe allergic
(anaphylactic) reactions.
Vaccine associated paralytic polio (VAPP)
(1/million) only in unvaccinated children
Disseminated disease in
immunosuppressed (CGD, IFN gamma
defects)






*By short supply, we simply mean that there are limits on the amount that can
actually be purchased in the short run, making vaccine availability a separate
constraint, in addition to money. This is the case today for COVID-19–specific
vaccines, with important implications for equity.
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calculations of the number of deaths averted per 1,000 individuals
immunized. Lee et al. (76) concluded, for example, that at 16.5
deaths averted per 1,000 immunizations (first dose), measles had
the highest performance by this metric. Costs, and sometimes,
dollar-valued benefits are added to complete the analysis. De-
livery complexity, such as cold-chain requirements or ease of
administration (as with OPV), will often play an important role in
addition to costs narrowly defined (79). Some of the specific
vaccines now licensed for use against COVID-19 require excep-
tional refrigeration with attendant cost and noncost barriers to
implementation. LAV use against COVID-19 will, if proven effec-
tive, have significant advantages on the cost side of the economic
evaluation.
Distinctive features that are typical for nonpathogen-specific
use of existing LAVs (but not for pathogen-specific vaccines) will in
all likelihood play an important part in economic evaluations.
These features include (depending on the LAVs):
• Effectiveness against multiple pathogens;
• More rapid elicitation of a protective immunity;
• Well-understood safety profiles;
• Population familiarity with and acceptance of many of the LAVs;
• Preexisting manufacturing capacity and licensing; and,
• Possibility that (current or future) vaccine stockpiles could be
diverted to pandemic responses.
Assessment of value for money depends critically on the spe-
cifics of proposed use. Table 4 summarizes possible uses of LAVs
against COVID-19 into four broad categories: 1) bridge (while
waiting for COVID-19 specific vaccine, or should the new vaccine
fail or not be deployed); 2) to boost response to COVID-19 specific
vaccine; 3) as a quick response ring vaccination of a specific pop-
ulation to contain an outbreak; and 4) potentially therapeutically or
as postexposure prophylaxis. Initial (and still ongoing) economic
evaluation of the first and third uses are pointing to favorable BCA
ratios. This appears to result from a (plausibly) high number of
deaths averted per 1,000 immunizations and from the exceptionally
low cost of most of the existing LAVs. It is worth adding an obser-
vation concerning ring use. Responding to sudden disease flare-
ups require effective containment of the outbreak before it has a
chance to spread. The immediate effectiveness of LAVs provides an
important advantage over slower acting (10 to 20 d) pathogen-
specific vaccines. This suggests a potential role for LAV vaccina-
tion even after pathogen-specific vaccines are available. Before
they are available it would be the only feasible approach in addition
to ring “vaccination” with convalescent plasma or monoclonal
antibodies.
It is worth expanding on the potential use of LAVs in envi-
ronments, like today’s with COVID-19, where effective disease-
specific vaccines are becoming available. In this context, use of
LAVs could best be thought of not as substitutes for disease-
specific vaccines, but rather as complements to them. Two dif-
ferent but important pathways exist for a LAV to add protection to
a vaccination program that would otherwise offer only a single
vaccine. First, in a rapidly unfolding pandemic, early interventions
have important value in reducing secondary infections, as well as
infection in the person vaccinated. While the adaptive immune
system can take 3 to 6 wk to respond to a vaccine, this report has
stressed that the innate immune system response is almost im-
mediate. During a pandemic, 4 wk is a long time even if the
vaccine was immediately available. Simultaneous administration
of a COVID-19 vaccine and a LAV would add protection during
the critical period prior to effectiveness of the covid vaccine. This
is quantitatively important: during midpandemic the incidence of
COVID-19 infection can easily lie between 1 and 5 infections per
1,000 persons per month. Even a LAV with only 50% efficacy could
then prevent several more primary infections per 1,000 vaccinees
than would a vaccination schedule offering only a COVID-19
vaccine. With an Reff of 2, the total number of infections prevented
could be twice the number of primary infections prevented. And
even after 4 to 5 wk, the LAV could plausibly add effectiveness to
the COVID-19 vaccine alone.
COVID-19 vaccine manufacturing constraints and delivery lo-
gistics (two doses, cold-chain requirements) could plausibly leave
half or more of the world’s population unvaccinated by the end of
2021. A second complementary use for a LAV would then be to
provide protection during what will often be long delays prior to
administration of the COVID-19 series. Again, that use would not
be an alternative to a COVID-19 vaccine but a way of providing
interim protection with a two-vaccine schedule of “LAV soon,
COVID-19 vaccine when available.” OPV’s familiarity in many
parts of the world, low cost, and easy delivery logistics may make
it particularly suited to the role of first vaccine in a two-
vaccine schedule.
Three final but more general points on economics are worth
making. First, it is widely understood that the macroeconomic and
social consequences of COVID-19 have been severe. Cutler and
Summers (80) have documented this for the United States and Lau
and Xiong (81) have done so for China as a whole and by province.
Economic consequences in China, while less severe than in the
Table 4. Potential uses of live attenuated vaccines LAVs against COVID-19
Use Population addressed
“Bridge” use (until SARS-CoV-2–specific vaccine becomes available) General populations
• Responders (medical, fire, police)
• At-risk populations (hourly workers, gig workers, undocumented
residents)
OPV incremental to SARS-CoV-2 specific vaccine As an adjuvant concomitant to administration of a COVID-19 vaccine
• To boost responses in elderly or individuals with comorbidity
Ring use (ring use will generally require single administration of vaccines
in well-defined populations as a quick response to appearance of
infection)
Quenching postpandemic flare-ups
• Quenching prepandemic sparks
• Institutionalized elderly and caretakers
• Prisoners and guards
• Other institutionalized groups
Therapeutic use (hypothetical) • Infected individuals immunized early after detection of infection
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United States, are surprisingly large given the rapidity with which
the Chinese government brought the epidemic under control.
Second, economic evaluations increasingly include examination
of the impact on equity. Valuable as the COVID-19–specific vac-
cines are, early indications suggest that their introduction will
exacerbate inequity within and across countries. The potential low
cost and rapid availability and widespread acceptance of LAVs
suggest their potential for attenuating these inequities. Finally,
the massive public resources that have been dedicated to de-
veloping new vaccines with protectable intellectual property that
can generate large returns for the developing companies stands
in stark contrast to the paltry public resources that have been
dedicated to assessing the efficacy of existing generic LAVs. This
is likely due to both the economic benefits that accrue to the
developers of new technologies but also the scientific prestige
that accrues to the scientists. Public policy should recognize and
counteract these influences for the public good.
Conclusions and Recommendations
In the war against infectious disease, COVID-19–specific vaccines
are our preferred weapons of mass salvation. But they are not a
panacea. The quest for specific SARS-CoV-2 vaccines started as
soon as the sequence of the novel coronavirus was shared on
January 11, 2020. The development of several efficacious vac-
cines 10 mo after the sequence was published and subsequently
shared by the Chinese Center for Disease Control and Prevention
is an incredible scientific success.
Vaccines give hope that the pandemic will be halted within
a year or two, but we have also learned hard lessons about the
limitations inherent in the development of completely new vac-
cines. One of the most important limitations relates to the time
needed not only for the development, but for mass deployment.
Challenges include scaled-up manufacture, logistics of rollout,
vaccine nationalism, vaccine hesitancy, and governmental and
intergovernmental regulations to ensure equitable distribution
within and across countries.
Even in the case of a microorganism such as SARS-CoV-2, for
which it appears that the development of a vaccine is not partic-
ularly difficult, it is still a minimum of 1.5 to 2 y until a safe and
effective vaccine can be produced, tested, distributed, and
delivered to the global population. In this period of time, count-
less lives have been lost, and economic havoc has been unleashed
in the world economy. This could be even more tragic in the case
of a pandemic caused by a microorganism for which the devel-
opment of a vaccine is more difficult, transmission is more rapid,
or the herd immunity more difficult to achieve. This can always
happen in any future epidemic.
There are other unknown aspects about novel specific vac-
cines. In the case of COVID-19, most specific vaccines are focused
on the spike protein of SARS-CoV-2. There are unanswered
questions about the durability of antibodies to the spike protein,
based on its glycoprotein structure and high mannose side chains
reminiscent of the HIV glycoprotein 120 envelope protein (9, 82,
83) and the flu virus Hemagglutinin (10), to which antibodies last
less than 6 mo. A greater suspicion arises from studies of the
seasonal coronaviruses in which the spike antibodies have been
shown to lack durability (84) and by clinical evidence that these
antibodies decline within a few months (85). Furthermore,
the efficacy of specific vaccines in preventing infection and
onward spread remains to be demonstrated. Safety in pregnant
women—a high-risk group representing significant proportion of
healthcare and aged care workforce—has not been established.
Finally, if SARS-CoV-2 undergoes antigenic drift similar to influ-
enza viruses, vaccines targeting spike protein may lose their
effectiveness. Indeed, just weeks after the rollout of the first
COVID-19 vaccines, some variants of SARS-CoV-2 were found to
be partially resistant to immunity induced by the original strain,
prompting attempts to develop modified vaccines. In contrast,
the antigenically altered viruses will remain vulnerable to a robust
innate immune response, boosted by LAVs.
The above considerations prompted many to consider an
evaluation of the use of already available LAVs to protect not just
for SARS-CoV-2 but also for future pandemics, which will inevi-
tably occur. The potential benefits of LAVs in the battle against
pandemics include: 1) use as a bridge vaccination in the begin-
ning of a pandemic, until specific vaccines are developed; 2) to
boost responses in the at-risk groups, such as older adults and
those with certain comorbidities, for whom classic vaccination is
often inefficient; and 3) to be used in combination with specific
vaccines, increasing their effectiveness and durability of the im-
mune response. Another application of LAV-induced stimulation
of innate immunity would be emergency postexposure prophy-
laxis. Vaccination of asymptomatic contacts of a COVID-19 case or
a PCR+ individual could prevent or attenuate the disease. With
their nonspecific or heterologous effects in boosting innate im-
munity, LAVs could have an important role in health promotion.
Furthermore, from a logistical perspective, they can be immedi-
ately deployed if enough stocks were available. Many existing
vaccines that could be used for this purpose are inexpensive and
easy to administer (for example, the cost of one dose of OPV is
$0.15, and it can be easily delivered orally). Failing to consider
such a highly cost-effective intervention in the urgent battle
against pandemics would be a large negligence on the part of the
scientific and medical community.
The time from the emergence of a pathogen to mass de-
ployment of an effective LAV stimulating innate immunity could
be reduced to months instead of the 1.5 to 2.0 y for a specific
vaccine (Fig. 3). Such emergency vaccination with LAVs at the start
of new pandemics could only be possible if several scientific and
logistical issues are resolved upfront. They include ensuring that
immunocompromised individuals be protected from potential
side effects of live vaccines, as well as resolving supply issues.
Fig. 3. Specific vaccines against a new pathogen require extensive
preclinical and clinical development and scaling up their production.
Because of the urgency, some of the steps can be combined (e.g.,
phases 1 and 2, or 2 and 3 of clinical trials). On the other hand the
existing LAVs only need phase 3 trial of their efficacy. They can either
be stockpiled in advance or their manufacture could be ramped up in
parallel with testing. Therefore, LAVs can be deployed sooner and
used for bridge vaccination to provide (partial) protection and limit the
spread of the pandemics until the development of specific vaccines.
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Repurposing existing vaccines should not come at the cost of re-
ducing availability of vaccines for their primary indication. If a stra-
tegic stockpile of such vaccines were created ahead of time, the
response could be faster andmore effective. Vaccines preactivating
innate immune responses could potentially provide useful bridge
vaccination until the development of specific vaccines.
Comparative characteristics of existing LAVs and the specific
SARS-CoV-2 vaccines presented in this paper argue that they both
have important roles to play in our response to the pandemic.
One point is clear: There is immense readiness and massive fi-
nancial support for the novel specific vaccines, but very little for
the (nonspecific) LAVs, despite their potential to prevent needless
suffering and help mitigate social and economic carnage in any
future pandemic. Thus, support for this strategy to exploit the
nonspecific effect of LAVs to protect high-risk populations, such as
healthcare workers and the elderly, as well as low-income pop-
ulations worldwide, thereby reducing social and economic inequities,
rests on governments, philanthropy, and nonprofit foundations.
It is critically important from both scientific and public health
perspectives that we complete rigorous trials evaluating the ef-
fectiveness of LAVs in preventing COVID-19 or mitigating its se-
verity. The findings from these trials will inform if and how we
could incorporate LAVs into our toolkit against future pandemics.
It will never be possible for us to eradicate all pathogens, nor
should we attempt to do so. Instead, perhaps we can emulate
bats, whose robust innate immune system allows them to flourish
while playing host to a plethora of coronaviruses.
Data Availability. All study data are included in the article.
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